AHR and breast cancer: We have previously shown that ANI-7 (Fig. 1a), a HAH ligand of the AHR, is a potent (GI50 = 0.16 μM) and breast cancer selective (up to 300-fold when compared with other tumour types) growth inhibitor22, 23.